These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7627991)

  • 1. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.
    Krawczyk CM; Verstovsek S; Ujházy P; Maccubbin D; Ehrke MJ
    Cancer Immunol Immunother; 1995 Jun; 40(6):347-57. PubMed ID: 7627991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation.
    Ehrke MJ; Verstovsek S; Pocchiari SK; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Meer JM; Mihich E
    Int J Cancer; 1998 May; 76(4):579-86. PubMed ID: 9590137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2.
    Ehrke MJ; Verstovsek S; Zaleskis G; Ho RL; Ujházy P; Maccubbin DL; Mihich E
    Cancer Immunol Immunother; 1996 May; 42(4):221-30. PubMed ID: 8665569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice.
    Ehrke MJ; Verstovsek S; Maccubbin DL; Ujházy P; Zaleskis G; Berleth E; Mihich E
    Int J Cancer; 2000 Jul; 87(1):101-9. PubMed ID: 10861459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma.
    Ehrke MJ; Verstovsek S; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Mihich E
    Int J Cancer; 1995 Nov; 63(3):463-71. PubMed ID: 7591249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
    Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
    Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.
    Ehrke MJ; Verstovsek S; Ujházy P; Meer JM; Eppolito C; Maccubbin DL; Mihich E
    Cancer Immunol Immunother; 1998 Feb; 45(6):287-98. PubMed ID: 9490198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
    Ho RL; Maccubbin D; Zaleskis G; Krawczyk C; Wing K; Mihich E; Ehrke MJ
    Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
    Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy.
    Chen JJ; Saeki Y; Shi LF; Köhler H
    J Immunol; 1989 Aug; 143(3):1053-7. PubMed ID: 2745974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide eradicates murine immunogenic tumor coding for a non-self-antigen and induces antitumor immunity.
    Salem ML; El-Naggar SA; Mahmoud HA; Elgharabawy RM; Bader AM
    Int J Immunopathol Pharmacol; 2018; 32():2058738418796591. PubMed ID: 30270681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA; Taylor PA; Aukerman SL; Blazar BR
    Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.
    Kadhim S; Penney C; Lagraoui M; Heibein J; Attardo G; Zacharie B; Connolly T; Gagnon L
    Int J Immunopharmacol; 2000 Sep; 22(9):659-71. PubMed ID: 10884587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
    Lasek W; Sora M; Wańkowicz A; Jakóbisiak M
    Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
    Runyon K; Lee K; Zuberek K; Collins M; Leonard JP; Dunussi-Joannopoulos K
    Blood; 2001 Apr; 97(8):2420-6. PubMed ID: 11290606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.